NEYROBLASTGX LLC

MURRIETA, CA · Biotech · Private

hOPSense: a human pluripotent stem cell-derived 3D gastrointestinal tract organoid system with integrated microfluidics-based electroconductance sensing for pathogen response detection

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · neyroblastgx.com

Sector: Biotech
Headquarters: MURRIETA, CA
Total capital: $645K

Federal grants: $645K; 3 awards · 2020–2021; Rank in peer group#7 of 24
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 4 pending

Capital timeline

Latest events

Mar 2021Federal grantNSF · Phase I · SBIR Phase I: Genetically Engineered Dendritic Cell to Activate SARS-CoV-2 Spike Protein specific-T Cell (COVID-19)$256K
Mar 2021Federal grantDefense · Phase I · hOPSense – A Human Organoid System for Detecting Pathogens Using an Electroconductive Microfluidic Array$223K
Dec 2020Federal grantDefense · Phase I · CoViRCureâ An Immunoprotective Oral Supplement for Reducing COVID-19 Post-Hyperimmunity Period Immune Suppression$166K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 24 peers

Line = median

Biotech · Device

Federal grants#7 · top 29%
Linked publications#1 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 4

Oct 16, 2025PendingHuman Brain Organoid, methods for making the brain organoid, and methods of using the brain organoid for high throughput rapid screening and/or evaluation of agentsUSPTOApplication 18980932
PendingGenetically Engineered Dendritic Cells From Human Induced Pluripotent Stem Cells To Activate SARS-COV-2 Protein-specific T Cells To Treat COVID-19USPTOApplication 63366127
PendingGenetically Engineered Dendritic Cells From Human Induced Pluripotent Stem Cells To Activate SARS-COV-2 Protein-specific T Cells To Treat COVID-19USPTOApplication 63365327

Show all 4 patent records

Human Brain Organoid, methods for making the brain organoid, and methods of using the brain organoid for high throughput rapid screening and/or evaluation of agentsOct 16, 2025 · Application 18980932Pending
Genetically Engineered Dendritic Cells From Human Induced Pluripotent Stem Cells To Activate SARS-COV-2 Protein-specific T Cells To Treat COVID-19Application 63366127Pending
Genetically Engineered Dendritic Cells From Human Induced Pluripotent Stem Cells To Activate SARS-COV-2 Protein-specific T Cells To Treat COVID-19Application 63365327Pending
Fully Functional Contractile Gastrointestinal Organoid System Generated From Human Induced Pluripotent Stem Cells To Develop A High Throughput System For Detecting Newly Emerging PathogensApplication 63365328Pending

Recent research by its founders

P2‐255: ULTRASENSITIVE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE USING CARBON NANOTUBE‐BASED BIOSENSOR ARRAYS20191 cites
Deriving Neural Cells from Pluripotent Stem Cells for Nanotoxicity Testing20187 cites
P4‐271: ULTRASENSITIVE AND ACCURATE ALZHEIMER'S DISEASE DIAGNOSTICS: FROM BENCH TO BEDSIDE20180 cites

Sunstone Therapies, Inc.Similar federal contract value in Biotech · null in contracts
EvodiaBioSimilar federal contract value in Biotech · null in contracts
MYCOBACTERIA THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
Eumentis Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Perfuse Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
CANTEX PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.